It did seem to reduce the risk of major heart attacks, but at the expense of major bleeding problems.

FORBES: Why Xarelto for ACS was doomed to fail

Harlan Krumholz, a cardologist at Yale, says he thinks the best role for the drug will be in patients who are at highest risk of heart attacks, as well as the lowest risk of bleeding.

FORBES: Magazine Article